BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Tarlatamab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Tarlatamab\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06830694-2753@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Tarlatamab: Phase 2 readout est. (NCT06830694)
DESCRIPTION:Tarlatamab\, phase 2\, Small Cell Lung Cancer.\nStudy: Clinical
  Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With
  Etoposide\, Carboplatin and Atezolizumab in Transformed Small Cell Lung C
 ancer Patients From Adenocarcinoma After EGFR TKI Treatment\nEstimated pri
 mary completion: 31 March 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/tarlatamab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06830694
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06598306-2753@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20270424
DTEND;VALUE=DATE:20270425
SUMMARY:Tarlatamab: Phase 1 readout est. (NCT06598306)
DESCRIPTION:Tarlatamab\, phase 1\, Small Cell Lung Cancer.\nStudy: Subcutan
 eous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cance
 r (DeLLphi-308)\nEstimated primary completion: 24 April 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/tarlatamab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06598306
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07016230-2753@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20270518
DTEND;VALUE=DATE:20270519
SUMMARY:Tarlatamab: Phase 2 readout est. (NCT07016230)
DESCRIPTION:Tarlatamab\, phase 2\, Small Cell Lung Cancer.\nStudy: Study In
 vestigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advan
 ced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroend
 ocrine Carcinomas (NECs)\, With Biomarker Analysis to Characterize Respons
 e/Resistance (UNLOCK TARLATAMAB)\nEstimated primary completion: 18 May 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/tarlatamab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07016230
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07803848-2753@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20270729
DTEND;VALUE=DATE:20270730
SUMMARY:Tarlatamab: Phase 2 readout est. (NCT07803848)
DESCRIPTION:Tarlatamab\, phase 2\, Small Cell Lung Cancer.\nStudy: Study to
  Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With
  Extensive Stage Small-cell Lung Cancer With Poor Performance Status\nEsti
 mated primary completion: 29 July 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/tarlatamab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07803848
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07111507-2753@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Tarlatamab: Phase 2 readout est. (NCT07111507)
DESCRIPTION:Tarlatamab\, phase 2.\nStudy: A Study of Tarlatamab for People 
 With Prostate Cancer\nEstimated primary completion: 31 August 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/tarlatamab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07111507
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07778316-2753@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20270924
DTEND;VALUE=DATE:20270925
SUMMARY:Tarlatamab: Phase 3 readout est. (NCT07778316)
DESCRIPTION:Tarlatamab\, phase 3\, Small Cell Lung Cancer.\nStudy: Phase 3 
 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer A
 fter Platinum Based First-line Chemotherapy (ES-SCLC)\nEstimated primary c
 ompletion: 24 September 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/tarlatamab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07778316
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05060016-2753@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Tarlatamab: Phase 2 readout est. (NCT05060016)
DESCRIPTION:Tarlatamab\, phase 2\, Small Cell Lung Cancer.\nStudy: A Phase 
 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)\nEsti
 mated primary completion: 30 December 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/tarlatamab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05060016
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03319940-2753@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tarlatamab: Phase 1 readout est. (NCT03319940)
DESCRIPTION:Tarlatamab\, phase 1\, Small Cell Lung Cancer.\nStudy: Study Ev
 aluating Safety\, Tolerability and Pharmacokinetics (PK) of Tarlatamab in 
 Adults With Small Cell Lung Cancer (SCLC)\nEstimated primary completion: 3
 1 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tarl
 atamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT03319940
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07423585-2753@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tarlatamab: Phase 2 readout est. (NCT07423585)
DESCRIPTION:Tarlatamab\, phase 2\, Small Cell Lung Cancer.\nStudy: Tarlatam
 ab for the Treatment of Extensive Stage Small-cell Lung Cancer\nEstimated 
 primary completion: 31 December 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/tarlatamab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07423585
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06816394-2753@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tarlatamab: Phase 2 readout est. (NCT06816394)
DESCRIPTION:Tarlatamab\, phase 2.\nStudy: Tarlatamab for Advanced Extrapulm
 onary Small Cell Carcinoma and Neuroendocrine Carcinoma (TAURUS)\nEstimate
 d primary completion: 31 December 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/tarlatamab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06816394
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06776250-2753@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20280303
DTEND;VALUE=DATE:20280304
SUMMARY:Tarlatamab: Phase 2 readout est. (NCT06776250)
DESCRIPTION:Tarlatamab\, phase 2.\nStudy: Study of How Safe and Effective T
 arlatamab is in Brain Cancers\nEstimated primary completion: 3 March 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/tarlatamab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06776250
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07037758-2753@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20280318
DTEND;VALUE=DATE:20280319
SUMMARY:Tarlatamab: Phase 1 readout est. (NCT07037758)
DESCRIPTION:Tarlatamab\, phase 1\, Small Cell Lung Cancer.\nStudy: A Study 
 of Tarlatamab in Combination With AB248 in Participants With Extensive Sta
 ge Small Cell Lung Cancer (DeLLphi-311)\nEstimated primary completion: 18 
 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tarlatama
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 037758
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06957314-2753@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20280423
DTEND;VALUE=DATE:20280424
SUMMARY:Tarlatamab: Phase na readout est. (NCT06957314)
DESCRIPTION:Tarlatamab\, phase na\, Small Cell Lung Cancer.\nStudy: A Study
  of Hospital-at-Home for People Receiving Tarlatamab\nEstimated primary co
 mpletion: 23 April 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/tarlatamab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06957314
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06788938-2753@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20280424
DTEND;VALUE=DATE:20280425
SUMMARY:Tarlatamab: Phase 2 readout est. (NCT06788938)
DESCRIPTION:Tarlatamab\, phase 2.\nStudy: Tarlatamab in Advanced Delta-like
  3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms\nEstimated 
 primary completion: 24 April 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/tarlatamab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06788938
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07531095-2753@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20280521
DTEND;VALUE=DATE:20280522
SUMMARY:Tarlatamab: Phase 1 readout est. (NCT07531095)
DESCRIPTION:Tarlatamab\, phase 1\, Small Cell Lung Cancer.\nStudy: Study of
  Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in S
 mall Cell Lung Cancer (SCLC)\nEstimated primary completion: 21 May 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/tarlatamab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07531095
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06551142-2753@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20281016
DTEND;VALUE=DATE:20281017
SUMMARY:Tarlatamab: Phase 1 readout est. (NCT06551142)
DESCRIPTION:Tarlatamab\, phase 1.\nStudy: A Study of GSK5764227 in Particip
 ants With Advanced Solid Tumors (EMBOLD)\nEstimated primary completion: 16
  October 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tarlat
 amab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06551142
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07005128-2753@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20290104
DTEND;VALUE=DATE:20290105
SUMMARY:Tarlatamab: Phase 3 readout est. (NCT07005128)
DESCRIPTION:Tarlatamab\, phase 3\, Small Cell Lung Cancer.\nStudy: A Study 
 Comparing Tarlatamab\, Durvalumab\, Carboplatin\, and Etoposide Versus Dur
 valumab\, Carboplatin\, and Etoposide in First-line Extensive Stage Small-
 Cell Lung Cancer (ES-SCLC)\nEstimated primary completion: 4 January 2029. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/tarlatamab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07005128
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07402343-2753@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Tarlatamab: Phase 2 readout est. (NCT07402343)
DESCRIPTION:Tarlatamab\, phase 2\, Small Cell Lung Cancer.\nStudy: Tarlatam
 ab for SCLC Brain Metastases\nEstimated primary completion: February 2029.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/tarlatamab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07402343
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06937905-2753@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20290201
DTEND;VALUE=DATE:20290202
SUMMARY:Tarlatamab: Phase 3 readout est. (NCT06937905)
DESCRIPTION:Tarlatamab\, phase 3.\nStudy: Tarlatamab vs Standard of Care Ch
 emotherapy in Patients With Pre-treated Advanced\, Pulmonary or Gastroente
 ropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)\nEstim
 ated primary completion: 1 February 2029. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/tarlatamab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06937905
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06893783-2753@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Tarlatamab: Phase 2 readout est. (NCT06893783)
DESCRIPTION:Tarlatamab\, phase 2.\nStudy: Efficacy and Safety Evaluation of
  Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma Patients\n
 Estimated primary completion: 30 April 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/tarlatamab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06893783
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07788677-2753@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20290501
DTEND;VALUE=DATE:20290502
SUMMARY:Tarlatamab: Phase 1 readout est. (NCT07788677)
DESCRIPTION:Tarlatamab\, phase 1.\nStudy: Tarlatamab Treatment Before and A
 fter Surgery in Surgically Resectable Recurrent High-grade Glioma: a Windo
 w of Opportunity Study (TARLAGLIA Study)\nEstimated primary completion: 1 
 May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tarlatamab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0778
 8677
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06745323-2753@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20290810
DTEND;VALUE=DATE:20290811
SUMMARY:Tarlatamab: Phase 2 readout est. (NCT06745323)
DESCRIPTION:Tarlatamab\, phase 2\, Small Cell Lung Cancer.\nStudy: A Phase 
 2\, Open-label\, Randomized\, Multicenter Study of Tarlatamab Dosing Regim
 ens in Subjects With SCLC\nEstimated primary completion: 10 August 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/tarlatamab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06745323
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07243470-2753@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Tarlatamab: Phase 1/2 readout est. (NCT07243470)
DESCRIPTION:Tarlatamab\, phase 1/2.\nStudy: Combination of Tarlatamab and T
 emozolomide in Patients With Central Nervous System Tumors\nEstimated prim
 ary completion: October 2029. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/tarlatamab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07243470
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07203053-2753@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Tarlatamab: Phase 2 readout est. (NCT07203053)
DESCRIPTION:Tarlatamab\, phase 2\, Small Cell Lung Cancer.\nStudy: A Trial 
 of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung 
 Cancer (ES-SCLC) and ECOG PS 2\nEstimated primary completion: October 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/tarlatamab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07203053
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06211036-2753@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20300402
DTEND;VALUE=DATE:20300403
SUMMARY:Tarlatamab: Phase 3 readout est. (NCT06211036)
DESCRIPTION:Tarlatamab\, phase 3\, Small Cell Lung Cancer.\nStudy: Study Co
 mparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Ex
 tensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum\, Etopos
 ide and Durvalumab\nEstimated primary completion: 2 April 2030. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/tarlatamab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06211036
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06117774-2753@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20300420
DTEND;VALUE=DATE:20300421
SUMMARY:Tarlatamab: Phase 3 readout est. (NCT06117774)
DESCRIPTION:Tarlatamab\, phase 3\, Small Cell Lung Cancer.\nStudy: Study Ev
 aluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lu
 ng Cancer (LS-SCLC)\nEstimated primary completion: 20 April 2030. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/tarlatamab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06117774
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06814496-2753@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Tarlatamab: Phase 1/2 readout est. (NCT06814496)
DESCRIPTION:Tarlatamab\, phase 1/2.\nStudy: Radiation Combined With BIspeci
 fic T-Cell Engager in DLL3 Expressing Tumors\nEstimated primary completion
 : May 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tarlatama
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 814496
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05361395-2753@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20300530
DTEND;VALUE=DATE:20300531
SUMMARY:Tarlatamab: Phase 1 readout est. (NCT05361395)
DESCRIPTION:Tarlatamab\, phase 1\, Small Cell Lung Cancer.\nStudy: First-Li
 ne Tarlatamab in Combination With Carboplatin\, Etoposide\, and PD-L1 Inhi
 bitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)\nE
 stimated primary completion: 30 May 2030. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/tarlatamab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05361395
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07242547-2753@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Tarlatamab: Phase 2 readout est. (NCT07242547)
DESCRIPTION:Tarlatamab\, phase 2\, Small Cell Lung Cancer.\nStudy: Study of
  Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited 
 Stage SCLC Patients\nEstimated primary completion: 1 June 2030. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/tarlatamab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07242547
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07226999-2753@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20300614
DTEND;VALUE=DATE:20300615
SUMMARY:Tarlatamab: Phase 2/3 readout est. (NCT07226999)
DESCRIPTION:Tarlatamab\, phase 2/3\, Small Cell Lung Cancer.\nStudy: Symbio
 tic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 
 in Combination With Chemotherapy and With Tarlatamab\, Alone or With Chemo
 therapy\, in Adult Participants With Extensive-Stage Small Cell Lung Cance
 r\nEstimated primary completion: 14 June 2030. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/tarlatamab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07226999
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07788365-2753@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Tarlatamab: Phase 2 readout est. (NCT07788365)
DESCRIPTION:Tarlatamab\, phase 2.\nStudy: Tarlatamab in Recurrent Gynecolog
 ical Neuroendocrine Carcinomas: A Phase II Proof-of-concept Study\nEstimat
 ed primary completion: 31 August 2030. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/tarlatamab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07788365
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06898957-2753@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20310623
DTEND;VALUE=DATE:20310624
SUMMARY:Tarlatamab: Phase 1 readout est. (NCT06898957)
DESCRIPTION:Tarlatamab\, phase 1\, Small Cell Lung Cancer.\nStudy: Study of
  Tarlatamab in Combination With YL201 With or Without Anti-programmed Deat
 h Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lu
 ng Cancer (SCLC)\nEstimated primary completion: 23 June 2031. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/tarlatamab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06898957
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07699237-2753@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20310630
DTEND;VALUE=DATE:20310701
SUMMARY:Tarlatamab: Phase 2 readout est. (NCT07699237)
DESCRIPTION:Tarlatamab\, phase 2\, Small Cell Lung Cancer.\nStudy: A Multic
 enter Phase II Trial to Evaluate Rechallenge With Platinum-based Chemother
 apy (Carboplatin\, Etoposide) for Progression During Tarlatamab Therapy in
  Relapsed Extensive Disease Small-cell Lung Cancer (SCLC)\nEstimated prima
 ry completion: 30 June 2031. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/tarlatamab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07699237
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07895056-2753@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20310831
DTEND;VALUE=DATE:20310901
SUMMARY:Tarlatamab: Phase 2 readout est. (NCT07895056)
DESCRIPTION:Tarlatamab\, phase 2\, Small Cell Lung Cancer.\nStudy: A Study 
 to Assess Adverse Events and Change in Disease Activity of Intravenous (IV
 ) ABBV-706 in Combination With Tarlatamab and Atezolizumab in Adult Partic
 ipants With Extensive Stage-Small Cell Lung Cancer\nEstimated primary comp
 letion: August 2031. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 tarlatamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07895056
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07637513-2753@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20371130
DTEND;VALUE=DATE:20371201
SUMMARY:Tarlatamab: Phase 3 readout est. (NCT07637513)
DESCRIPTION:Tarlatamab\, phase 3\, Small Cell Lung Cancer.\nStudy: Tarlatam
 ab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung C
 ancer\nEstimated primary completion: November 2037. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/tarlatamab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07637513
URL:https://assetmemo.bio/drug/tarlatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
